Dyne therapeutics linkedin
WebDyne Therapeutics 5,434 followers on LinkedIn. Advancing life-transforming therapies for serious muscle diseases Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is … WebApr 11, 2024 · Dyne Therapeutics has a 52-week low of $4.30 and a 52-week high of $15.63. Dyne Therapeutics ( NASDAQ:DYN - Get Rating ) last issued its quarterly earnings data on Thursday, March 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.10.
Dyne therapeutics linkedin
Did you know?
WebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving average of $12.09. The firm has a market ... WebDyne Therapeutics 5 years 3 months Vice President - Head of Platform Development Dyne Therapeutics Feb 2024 - Present 3 months. Waltham, Massachusetts, United States ...
WebSep 12, 2024 · As a result, Dyne expects its cash runway will be extended through 2024 and plans to provide an update on its FSHD program in 2024. About Dyne Therapeutics. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. WebGet the latest Dyne Therapeutics Inc (DYN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
WebMar 20, 2024 · About Dyne Therapeutics. ... LinkedIn and Facebook. Forward-Looking Statements. This press release contains forward-looking statements that involve substantial risks and uncertainties. All ... WebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended …
WebJan 18, 2024 · WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed on …
WebARF Manager. Genocea Biosciences. Sep 2024 - Feb 20243 years 6 months. Cambridge, MA. orchidfoodservicesWebMar 20, 2024 · linkedin.com twitter.com facebook.com; Focused on muscle and. ... Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing … ir8a 2023 submissionWebApr 2024 - Aug 20245 months. Boston, Massachusetts, United States. Contracted to develop program and commercial strategies for bone health projects and drug programs. Reported to Chief Business ... ir850 infrared illuminatorWebSenior Clinical Research Associate. PAREXEL. ott 2008 - ott 20102 anni 1 mese. Sydney, AUSTRALIA. orchidfallWebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1). ir8a submission dateWebJul 5, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … orchidfrequency okcupid strapWebAlnylam Pharmaceuticals. Jun 2008 - Jun 20157 years 1 month. Cambridge, MA. Set up group and practices and responsible for running following corporate functions: - Business … ir850 infrared illuminator for atn